Xenon Pharmaceuticals announced top-line Phase 3 results for azetukalner showing large, statistically robust reductions in focal onset seizure frequency versus placebo and plans an FDA filing later this year. The company said the 25 mg and 15 mg doses cut seizure rates by roughly 53% and 34%, respectively, versus a ~10% placebo effect, and described the outcome as exceeding expectations. Xenon characterized the safety profile as manageable and singled out the 15 mg dose as commercially attractive because of a lower discontinuation rate. The data markedly de-risk a regulatory filing and position azetukalner as a potential new oral mechanism in epilepsy (KV7 potassium channel opener). The company has signaled an intent to submit an NDA in Q3 and expects the results to support broad label claims for focal seizures. Investors responded with a substantial share-price rally following the readout, underscoring the commercial market opportunity for improved anti-seizure therapies. Named sources: Xenon Pharmaceuticals press releases and clinical study top-line data. For clarity, focal onset seizures are a common, often treatment‑resistant epilepsy subtype where new mechanisms of action can meaningfully change the therapeutic landscape.